About

The Campbell lab studies how the brain self-assembles through a carefully orchestrated balance of extrinsic guidance and intrinsic imperatives. They focus on understanding the regulatory networks that direct brain development and how disruptions in these processes can lead to neurological disorders. The lab uses stem cell and mouse models to investigate cellular specification, with a particular interest in the intersection of extrinsic and intrinsic signals and their connection to human disease. Their research aims to elucidate the mechanisms underlying neurodevelopmental disorders such as autism, with the goal of informing treatment and prevention strategies.

Research topics

• Medicine
• Internal medicine
• Psychiatry
• Psychotherapist
• Demography
• Environmental health
• Pediatrics
• Physical therapy
• Psychology
• Gerontology
• Nursing

Selected publications

• Preexisting Mild Cognitive Impairment, Dementia, and Receipt of Treatments for Acute Ischemic Stroke

  Stroke · 2021 · 17 citations

  • Medicine
  • Internal medicine
  • Physical therapy

  BACKGROUND AND PURPOSE: Differences in acute ischemic stroke (AIS) treatment by cognitive status are unclear, but some studies have found patients with preexisting dementia get less treatment. We compared AIS care by preexisting cognitive status. METHODS: Cross-sectional analysis of prospectively obtained data on 836 adults ≥45 with AIS from the population-based Brain Attack Surveillance in Corpus Christi project from 2008 to 2013. We compared receipt of a composite quality measure representing the percentage of 7 treatments/procedures received (ordinal scale; values, <0.75, 0.75-0.99, and 1.0), a binary defect-free quality score, and individual treatments after AIS between patients with preexisting dementia (Informant Questionnaire on Cognitive Decline in the Elderly score ≥3.44), mild cognitive impairment (MCI, score 3.1-3.43), and normal cognition (score ≤3). RESULTS: <0.001). CONCLUSIONS: Patients with preexisting MCI and dementia, compared with cognitively normal patients, may receive less frequently some treatments and procedures, but not the composite quality measure, after AIS.

  DOI

• Temporal Trends in Ischemic Stroke Rates by Ethnicity, Sex, and Age (2000–2017)

  Neurology · 2021 · 21 citations

  • Medicine
  • Demography
  • Gerontology

  OBJECTIVE: To compare 18-year (2000-2017) temporal trends in ischemic stroke rates by ethnicity, sex, and age. METHODS: Data are from a population-based stroke surveillance study conducted in Nueces County, Texas, a geographically isolated, biethnic, urban community. Active (screening hospital admission logs, hospital wards, intensive care units) and passive (screening inpatient/emergency department discharge diagnosis codes) surveillance were used to identify cases aged ≥45 (n = 4,875) validated by stroke physicians using a consistent stroke definition over time. Ischemic stroke rates were derived from Poisson regression using annual population counts from the US Census to estimate the at-risk population. RESULTS: = 0.02) in the 2 older age groups, while rates did not change in either sex in those age 45-59. CONCLUSION: Previously documented ethnic stroke incidence disparities have ended as a result of declining rates in Mexican Americans and increasing rates in non-Hispanic Whites, most notably in midlife.

  DOI

• The Ethic of Access: An AIDS Activist Won Public Access to Experimental Therapies, and This Must Now Extend to Psychedelics for Mental Illness

  Frontiers in Psychiatry · 2021 · 10 citations

  1st authorCorresponding
  • Psychiatry
  • Medicine
  • Psychology

  If patients with mental illnesses are to be treated fairly in comparison with other categories of patients, they must be given access to promising experimental therapies, including psychedelics. The right of early access to promising therapies was advanced as an ethical principle by activist Larry Kramer during the AIDS pandemic, and has now largely been adopted by the medical establishment. Patients are regularly granted access to experimental drugs for many illness categories, such as cancer and infectious diseases. The need for expanded access is especially relevant during evolving crises like the AIDS and the coronavirus pandemics. In contrast to non-psychiatric branches of medicine, psychiatry has failed to expedite access to promising drugs in the face of public health emergencies, psychological crises, the wishes of many patients, and the needs of the community. Psychiatry must catch up to the rest of medicine and allow the preferences of patients for access to guide policy and law regarding unapproved medications like psychedelics.

  DOI

Frequent coauthors

• James C. Grotta

  Memorial Hermann

  36 shared

• Elizabeth A. Noser

  32 shared

• Hashem Shaltoni

  The University of Texas Medical Branch at Galveston

  32 shared

• Raymond U. Weir

  Michael E. DeBakey VA Medical Center

  27 shared

• Nicole R. Gonzales

  Baylor Scott & White Health

  27 shared

• Karen C. Albright

  SUNY Upstate Medical University

  26 shared

• Aslam M. Khaja

  Alexian Brothers Health System

  26 shared

• Sean I. Savitz

  25 shared

Education

• MD

  New York University School of Medicine

  2016

• PhD, Genetics and Development

  New York University

  2016

Awards & honors

• NIH U54CA272220 (2022-2027)
• NIH R03ES036405 (2024)
• NIH R00MH126430 (2021-2026)

Similar researchers at University of California, San Diego

• Ronald M. Evansh-300
• Rob Knighth-297
• Michael (Geoff) Rosenfeldh-224
• Don W. Clevelandh-213
• Anders M Daleh-209